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Abstract
Purpose Cognitive functioning is increasingly investigated for its prognostic value in glioblastoma (GBM) patients, but the 
association of cognitive status during early adjuvant treatment with survival time is unclear. The aim of this study was to 
determine whether cognitive performance three months after surgical resection predicted survival time, while using a clini-
cally intuitive time ratio (TR) statistic.
Methods Newly diagnosed patients with GBM undergoing resection between November 2010 and February 2018 completed 
computerized cognitive assessment 3 months after surgery with the CNS Vital Signs battery (8 measures). The association 
of cognitive performance (continuous Z scores and dichotomous impairment status; impaired vs. unimpaired) with survival 
time was assessed with multivariate Accelerated Failure Time (AFT) models that also included clinical prognostic factors 
and covariates related to cognitive performances.
Results 114 patients were included in the analyses (median survival time 16.4 months). Of the clinical factors, postoperative 
Karnofsky Performance Status (TR 1.51), surgical (TR 2.20) and non-surgical (TR 1.94) salvage treatment, and pre-surgical 
tumor volume  (cm3, TR 1.003) were significant independent predictors of survival time. Independently of the base model 
factors and covariates, impairment on Stroop test I and Stroop test III estimated 23% and 26% reduction of survival time 
(TR 0.77, TR 0.74) respectively, as compared to unimpaired performance.
Conclusion These findings suggest that impaired performances on tests of executive control and processing speed in the early 
phase of adjuvant treatment can reflect a worse prognostic outlook rather than an early treatment effect, and their assessment 
might allow for early refinement of current prognostic stratification.
Keywords Glioblastoma · Cognitive functioning · Survival · Karnofsky performance status · Brain tumor
Introduction
To date, functional performance status (PS) appears to be one 
of the few clinical factors consistently allowing for prognos-
tic stratification in the glioblastoma (GBM) population [1–3]. 
Despite methodological issues [4, 5], it has shown superior 
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predictive value compared to characteristics such as mac-
roscopic extent of resection [1] and patient age [3, 6]. Still, 
prognostic heterogeneity remains within clinically defined risk 
groups [7] and identification of other patient-related markers 
could advance clinical monitoring and decision-making.
Measures tapping into functional domains that underlie PS, 
such as fatigue and cognitive functioning, have been evaluated 
increasingly for their prognostic value in glioma [8, 9]. Poorer 
cognitive performance in treatment- naive patients appears 
to predict worse survival outcome [10, 11]. However, not all 
patients can be tested (validly) in the short period between 
diagnosis and start of treatment, and although pre-treatment 
cognitive dysfunction may reflect tumor status [9, 12], its 
nature or severity may be affected by distress from the diag-
nosis [9, 13] tumor laterality [14], or motor symptoms [12, 13].
After commencement of anti-tumor treatment, the over-
all cognitive profile of GBM patients remains characterized 
by high levels of impairment [15]. Multiple investigations 
have explored the significance of post-surgical cognitive 
(dys-)function for survival, mostly by targeting cognitive 
assessment between surgical debulking and start of (chemo-)
radiation. These studies have suggested a contribution of 
(impaired) cognitive performance, especially executive func-
tioning, to the estimation of hazard rates in (older) patients 
[16–20]. It remains unknown, however, whether cognitive 
status during early adjuvant treatment with radio- and/or 
chemotherapy bears value in predicting survival outcome.
Furthermore, although the commonly reported hazard 
ratio(HR) [10, 17–20] statistic provides information about 
the rates of death during follow up among patients with dif-
ferent cognitive performances, it does not directly translate 
into an estimation of differences in survival time. Consid-
ering the poor prognosis associated with GBM, readily 
interpretable information about survival duration can be of 
particular interest to clinicians. The accelerated failure time 
model (AFT) [21] allows for the immediate derivation of 
a time ratio (TR) that indicates if a variable is related to 
shorter or longer survival time, e.g., in months, which is 
arguably more clinically intuitive.
The current study employed AFT modeling to investigate 
whether cognitive performance three months after surgical 
resection predicts survival time in GBM patients, with the 
aim of contributing to our understanding of the prognostic 
value of cognitive performance during adjuvant treatment 
and early refinement of prognostic models.
Materals and methods
Study design
Data was obtained as part of a prospective longitudinal study 
in which patients with primary brain tumors underwent 
neuropsychological assessment (NPA) one day before (T0) 
and three months after surgery (T3) as part of usual care at 
Elisabeth-TweeSteden Hospital (Tilburg, the Netherlands). 
This study was approved by the local Medical Ethics Com-
mittee Brabant (file number NL41351.008.12).
Patients
For the current study, patients who underwent surgical 
resection of histopathologically confirmed GBM between 
November 2010 and February 2018, and who completed 
NPA at T3 were considered for inclusion. All included 
patients provided written informed consent. We excluded 
patients if at least one of the following criteria was met: 
age < 18, diagnosis of a progressive neurological disease, 
psychiatric or acute neurological disorder within the past 
2 years, previous intracranial surgery, or impaired testability 
(e.g., lack of proficiency in Dutch, estimated IQ < 85, serious 
visual or motor deficits). Part of the current sample has been 
described previously [15, 22].
Measures
Cognitive functioning
We measured cognitive performance with a computerized 
neuropsychological test battery (CNS Vital Signs, CNS VS) 
[23]. Content of the tests that were used are displayed in 
Online Resource 1. Test validity was evaluated by the test 
administrator at time of testing and documented in a sepa-
rate observation document. Invalid test performances were 
excluded. We used data from repeated assessment with CNS 
VS in healthy controls [24] for normative purposes. Based on 
these data, we computed Z-scores that were adjusted for age, 
sex and educational attainment for each test performance 
(M = 0, SD = 1). A Z-score ≤ − 1.5 (performance below 
the 7th percentile) was considered impaired, and Z-score 
between − 1 and − 1.49 (performance between 7 and 16th 
percentile) was considered low. Valid scores were not trun-
cated. The proportion of impaired performances relative to 
number of valid test scores per patient ( #impairedperformances
#validtests
) 
was calculated for descriptive purposes.
Clinical measures
We retrieved the following data from the electronic medi-
cal charts: tumor location, macroscopic extent of resection, 
KPS, anti-epileptic drug (AED) use, corticosteroid use, 
adjuvant treatment protocol, salvage treatment, and treat-
ment-related events (e.g., allergic reaction, infection, throm-
bocytopenia). Isocitrate dehydrogenase type 1 (IDH1) gene 
mutation status was retrieved from pathological reports. 
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We deterimed presurgical tumor volume (expressed in  cm3) 
through semi-automatic segmentation with BrainLab Ele-




Survival time was defined as the time between debulking 
and either date of death or last known contact before Febru-
ary 1st 2019 (in months). A survival curve displaying the 
proportion of patients surviving as a function of time was 
plotted.
Cognitive performance
We compared the mean performances of patients on each 
test to that of healthy controls with Z tests.
Accelerated failure time models
We used the Accelerated Failure Time (AFT) model to 
investigate differences in survival time between groups. The 
AFT model provides a baseline survivor function and an 
acceleration coefficient that indicates whether a covariate 
“accelerates” or “decelerates” time until death. The expo-
nentiated coefficient constitutes a time ratio (TR). TR < 1 
or TR > 1 indicates that a variable is related to shorter or 
longer survival time respectively, e.g., a TR of 0.70 means 
that patients with a certain characteristic are estimated to 
have a median survival time that is 70% of patients without 
that characteristic.
Data distribution
We fitted models that assumed different distributions 
(Exponential, Weibull, Lognormal, Log-logistic, Gamma 
and Gauss). The model that fitted the data best, while being 
parsimonious, was selected based on a comparison of fit 
statistics (Akaike Information Criterion, AIC).
Base model
An initial base model included known clinical predictors 
of survival, including age at time of surgery, pre-surgical 
tumor volume  (cm3), extent of resection (macroscopic total 
vs subtotal), KPS (at T3) (≤ 80 vs 90–100), adjuvant treat-
ment protocol (chemoradiation vs other), treatment-related 
events, and salvage therapy (none [as reference category], 
non-surgical, surgical). We kept variables that significantly 
predicted survival time (α = 0.05) in the base model.
Cognitive models
We added the performances on the tests (continuous Z 
scores and dichotomous impairment status; not impaired vs. 
impaired) to the base model separately. Before running the 
cognitive models, we investigated potential covariates (clini-
cal and sociodemographic variables that differed between 
impairment groups or were related to the Z scores): sex, 
low educational level, high educational level, affected hemi-
sphere, frontal involvement, corticosteroid use at T3, AED 
use at T3, and the clinical factors that were not significant 
predictors in the base model. Covariate analyses included 
ANOVA’s and (non-)parametric correlations (Z scores), in 
addition to independent samples t tests and Chi-Square tests 
(impairment status). If significantly related to the test perfor-
mance (α = 0.05), the covariate was added to the AFT model 
containing the relevant cognitive test score. We performed 
multiple testing corrections with the False Discovery Rate 
procedure by Benjamini and Hochberg [25] (separate cor-
rections for the Z-score models and the impairment models).
Multivariate estimation of median time to event (MTTE)
For a direct comparison of survival probabilities of patients 
who showed similar clinical characteristics, but different 
cognitive performances, we computed estimations of MTTE 
for the significant models and their predictors. Survival 
curves were plotted to visualize survival differences over 
time.
Analyses were conducted in SPSS Statisics v.24 and Rstu-
dio, using the survival [26] package.
Results
Sample
One hundred and fourteen patients with T3 data were 
included in the analyses (see Online Resource 2 for a flow-
chart, including reasons for dropout before T3 and exclu-
sion). Table 1 displays the sample characteristics.
Cognitive functioning
Average time between surgery and T3 measurement was 
3.03 months (95% CI 2.95–3.12 months). Table 2 pro-
vides group performances (mean Z scores) and impairment 
counts for all tests at T3. The number of valid performances 
ranged between n = 107 and n = 113. Invalid performances 
were the consequence of technical problems during a test, 
external distraction, not understanding or repeatedly forget-
ting the instructions of a test, color blindness (Stoop test III 
and Shifting Attention test only) and mild unilateral motor 
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disturbances (Finger Tapping test and Shifting Attention test 
only). Eighty-seven percent (n = 99) of patients displayed 
some degree of impairment (on at least one of the tests they 
completed); 38% (n = 43) on less than one third of the tests, 
16% (n = 18) on at least one third, but less than half of the 
tests, and 33% of patients (n = 38) showed impairment on at 
least half of the tests.
Survival
The lognormal distribution provided the lowest AIC 
among the tested models, indicating the best fit for the 
data. Figure 1 displays the survival probability over time 
(no predictors). The median survival time was 16.4 months 
(95% CI 13.90–18.85). At the defined time-point, 91 of 114 
patients were deceased (79.8%).
Base model
Of the included clinical variables, T3 KPS of 90–100 
(p < 0.001), salvage therapy (non-surgical and surgical) (p 
values < 0.001), and pre-surgical tumor volume (p = 0.02) 
were significant positive predictors of survival time (TR 
1.51, 1.94, 2.20, and 1.003 respectively). Age, extent of 
resection, adjuvant treatment protocol, and treatment-related 
events were not related to survival time (all p values > 0.05).
Cognitive model—continuous Z‑scores
Based on analyses of the covariates, we adopted the follow-
ing variables as covariates in the cognitive models: age at 
time of surgery (SDC, SAT, Stroop I, Stroop III), sex (SAT), 
right hemispheric tumor (VIM), and corticosteroid use at 
T3 (FTT). None of the eight continuous Z scores showed a 
significant independent relationship with survival time under 
the adjusted alpha level after B–H correction (α = 0.006; see 
Table 3). None of the included covariates showed a signifi-
cant independent contribution to prediction of survival time.
Cognitive status—impairment
Covariates for impairment status included age at time of 
surgery (SDC, Stroop I, Stroop III), sex (VIM), low edu-
cational level (SDC), right hemispheric tumor (Stroop I), 
corticosteroid use at T3 (VEM), extent of resection (VIM), 
and frontal involvement (CPT). Salvage treatment was 
significantly associated with less SDC, SAT, Stroop I and 
Stroop III impairment (p < 0.05), but was already part of the 
clinical model. As shown in Table 3, addition of impairment 
status and relevant covariates to the base model showed that 
impaired performance on Stroop I (p < 0.01, TR 0.77) and 
Stroop III (p < 0.01, TR 0.74) were independent negative 
predictors of survival time (i.e., decreasing survival dura-
tion) under the adjusted alpha level (α = 0.013). Tumor 
volume was not an independent predictor for survival time 
in the Stroop I and III models (p > 0.013), while KPS and 
salvage treatments remained significant (all p values < 0.01). 
None of the covariates showed a significant contribution to 
the prediction of survival time.
Multivariate estimation of median time to event 
(MTTE)
We estimated survival probabilities for patients with similar 
clinical characteristics, but different impairment status, using 
the predicted covariance matrices of all significant variables in 
Table 1  Patient characteristics
TMZ temozolomide
a ECOG/WHO functional status instead of KPS was reported for 6 
patients. This score was converted to KPS (ECOG 0 = KPS 90–100, 
ECOG 1 = KPS 80 or below).
b All patients had started adjuvant treatment before T3 NPA
Characteristic n = 114
Male n (%) 83 (73%)
Age at time of surgery (m ± SD, range) 58 ± 12, 18–80
Educational level
 Low n (%) 38 (33%)
 Middle n (%) 43 (38%)
 High n (%) 33 (29%)
Tumor volume  (cm3) Median (range) 35 (1–163)
Tumor lateralization n (%)
 Right 68 (60%)
 Left 46 (40%)
Frontal involvement n (%) 41 (36%)
IDH1 mutational status (n = 66)
 Wild-type n (%) 62 (94%)
KPS at  T3a (n = 111)
 80 or below 32 (29%)
 90–100 79 (71%)
AED use at T3 (n = 111) 41 (37%)
Corticosteroid use at T3 (n = 113) 46 (41%)
Macroscopic extent of resection
 Gross total resection (< 90%) 70 (61%)
 Gross subtotal resection (> 90%) 44 (39%)
Adjuvant  treatmentb
 Chemoradiation (followed by TMZ monotherapy) 104 (91%)
 Radiotherapy only 9 (8%)
 No adjuvant treatment 1 (1%)
Treatment-related event 12 (11%)
Salvage therapy (n = 113)
 No salvage therapy 62 (55%)
 Non-surgical (e.g., TMZ, lomustine, XRT) 29 (26%)
 Surgical (with or without additional treatment) 22 (19%)
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the Stroop I and Stroop III models. For example, a comparison 
is shown below of patients with KPS 90–100 (n = 79) who 
did not receive salvage therapy after progression, and either 
did show impairment (i.e., survival probability for patient 1, 
denoted by p1) or not (i.e., survival probability for patient 2, 
denoted by p2).
p1 = (KPS at T3 = 90 − 100, salvage therapy = none, cognitive status = impaired)
p2 = (KPS at T3 = 90 − 100, salvage therapy = none, cognitive status = unimpaired).
Stroop III test
Estimated MTTE for p1 was 12.1 months, compared to 
16.1 months for p2, reflecting an estimated shorter survival 
time of 4.0 months for the impaired performer.
Stroop I test
Estimated MTTE for p1 was 12.3 months, compared to 
15.9 months for p2, reflecting an estimated shorter survival 
of 3.6 months for the impaired performer.
We repeated this procedure for patients with KPS 90–100, 
who received non-surgical salvage therapy (MTTE = 22.8 
vs 30.5  months for Stroop III impaired vs. unimpaired 
performers, 22.5 vs. 28.9 months for Stroop I impaired 
vs. unimpaired performers), and surgical salvage therapy 
(MTTE = 23.7 vs. 31.7 months for Stroop III impaired vs. 
unimpaired performers, 24.2 vs. 31.2 months for Stroop I 
impaired vs unimpaired performers). See Fig. 2 for multi-
variate survival plots for the described scenarios. We did not 
perform estimations for patients with KPS ≤ 80 (n = 32) due 
to the lower sample size.
Table 2  Mean cognitive test scores (group level) and impairment counts
a Z score ≤ − 1.5
b − 1.49 ≤ Z-score ≤ − 1
c Z score ≥ − 0.99
** Significant difference from healthy control group as indicated by Z tests, p < .001






Verbal memory test (VEM) (n = 109) − 0.82 ± 1.27** 33 (30%) 13 (12%) 63 (58%)
Visual memory test (VIM) (n = 111) − 0.52 ± 1.04** 18 (16%) 22 (20%) 71 (64%)
Symbol Digit coding test (SDC) (n = 112) − 1.17 ± 1.27** 46 (41%) 14 (13%) 52 (46%)
Finger tapping test (FTT) (n = 112) − 0.94 ± 1.53** 34 (31%) 16 (14%) 62 (55%)
Shifting attention test (SAT) (n = 107) − 1.37 ± 1.79** 42 (39%) 10 (9%) 55 (52%)
Continuous performance test (CPT) (n = 113) − 1.32 ± 2.59** 39 (35%) 16 (14%) 58 (51%)
Stroop test part I (n = 112) − 1.66 ± 2.78** 47 (42%) 5 (4%) 60 (54%)
Stroop test part III (n = 109) − 1.77 ± 1.93** 56 (51%) 11 (10%) 42 (39%)
Fig. 1  Survival probability over time and estimated median survival 
time (censoring is indicated with +)
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Discussion
This study investigated to what extent cognitive performance 
three months after surgical resection was related to survival 
time in patients with GBM. We assessed the predictive value 
of cognition with AFT models while controlling for signifi-
cant clinical prognostic factors (KPS, pre-surgical tumor 
volume, and salvage therapy) and covariates. Eighty-seven 
percent of patients showed impairment on at least one test, 
while 33% showed impairment on at least half of the tests. 
In line with available literature, we found that impairment 
on a test of executive functioning [17, 19] (Stroop test III) 
independently predicted worse survival. We found a similar 
effect of processing speed (Stroop test I) impairment. Spe-
cifically, estimated median survival time was 26% shorter 
for patients with impairment on Stroop III compared to 
those without, and 23% shorter for patients with impair-
ment on Stroop I compared to those without, translating 
into decreases of at least 4.0 and 3.6 months respectively 
in patients of good postoperative functional status (KPS 
90–100), depending on salvage treatment. The continuous 
performance scores (Z-scores) did not reach the adjusted 
significance level, indicating that the prognostic bearing 
of cognition was limited to performances beyond a clinical 
threshold.
Taking into account previous reporting that patients 
with stable disease tend to show stable cognitive perfor-
mance during early adjuvant treatment [27] and that dys-
function arising before 6-month follow up appears related 
to poorer survival outcome [28], our results suggest that 
specific cognitive impairments during chemo-radiation 
reflect a worse prognostic outlook rather than an early 
treatment effect (otherwise due to e.g., acute encephalopa-
thy [29, 30] or treatment-induced fatigue [31]).
Notably, we found a relationship between cognitive 
impairment three months after surgery and salvage treat-
ment, but they both exhibited independent associations 
with survival time. Treatment decisions are partly based 
on the patient’s functional performance [3], which itself is 
associated with cognition [5], and clinicians might favor 
more radical treatment in patients with good cognitive sta-
tus [9]. Incorporating information about salvage treatment 
in studies involving cognition and survival outcome is 
therefore warranted. We note that the prognostic bearings 
of salvage treatment as well as postsurgical KPS appear 
larger than that of postsurgical cognitive impairment. 
Table 3  Multivariate analyses 
of cognitive performances and 
survival time
SE standard error, TR time ratio
a Model contained covariate(s), see Results section
Variable Coefficient (95% CI) SE TR p Model AIC
Base model
 KPS 90–100 at T3 (vs. ≤ 80) 0.41 (0.21–0.64) 0.11 1.51  < 0.001 614.3
 Salvage treatment (vs. none)
  Surgical 0.78 (0.53–1.04) 0.13 2.20  < 0.001
  Non-surgicalNon-surgical 0.66 (0.45–0.91) 0.12 1.94  < 0.001
 Volume (expressed in  cm3) 0.003 (− 0.001–0.005) 0.001 1.003 0.02
Cognitive model—Z scores
 Z score VEM 0.05 (− 0.02–0.12) 0.04 1.05 0.14 585.2
 Z score  VIMa − 0.02 (− 0.11–0.08) 0.05 0.98 0.71 599.2
 Z score SDC a 0.08 (0.00–0.16) 0.04 1.08 0.06 602.3
 Z score FTT a 0.02 (− 0.05–0.07) 0.01 1.01 0.68 599.1
 Z score SAT a − 0.01 (− 0.06–0.05) 0.03 0.99 0.73 578.4
 Z score CPT 0.01 (0.00–0.03) 0.02 1.01 0.72 607.2
 Z-score Stroop  Ia 0.01 (− 0.02–0.04) 0.02 1.02 0.53 610.1
 Z score Stroop III a 0.06 (0.00–0.11) 0.03 1.06 0.03 590.7
Cognitive model—impairment
 Impairment  VEMa − 0.19 (− 0.39–0.00) 0.10 0.83 0.07 577.0
 Impairment  VIMa 0.15 (− 0.12–0.42) 0.13 1.17 0.24 600.2
 Impairment  SDCa − 0.13 (− 0.33–0.06) 0.10 0.88 0.19 603.6
 Impairment FTT − 0.11 (− 0.29–0.11) 0.10 0.90 0.30 604.1
 Impairment  SATa 0.06 (− 0.12–0.27) 0.09 1.07 0.52 579.6
 Impairment  CPTa − 0.11 (− 0.30–0.08) 0.10 0. 90 0.28 607.4
 Impairment Stroop  Ia − 0.26 (− 0.46–0.08) 0.10 0.77  < 0.01 603.2
 Impairment Stroop  IIIa − 0.31 (− 0.48–0.09) 0.10 0.74  < 0.01 586.3
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Nevertheless, cognitive measures acquired in addition to 
routine clinical follow up may facilitate early refinement 
of prognosis. Submitting vulnerable patients to exhaustive 
assessment for this purpose may not be not necessary, as 
performance on a limited range of tests, those assessing 
executive functioning in particular [9], appear relevant.
Executive functioning encompasses and relies on vari-
ous functions. Part III of the Stroop test measures executive 
control ability; making decisions on relevant information 
among distracting cues. As it engages multiple functions 
such as top-down attention, response selection, inhibition 
and evaluation, executive control recruits a distributed net-
work involving the dorsolateral prefrontal cortex and ante-
rior cingulate cortex [32]. Stroop I does not involve execu-
tive control, as it mainly reflects the speed at which subjects 
identify that a target is present (simple processing speed). 
However, slowed processing speed contributes to executive 
functioning deficits [33] and decreased processing speed 
together with memory and executive dysfunction has been 
suggested as a marker for more advanced disease [34]. The 
Trail Making Test part B, a test that has been shown to carry 
particular value in predicting survival [11, 17], also puts a 
demand on executive function in addition to mental speed 
[35, 36].
We did not find significant predictive roles for other tests 
that strongly depend on information processing speed, such 
as the Symbol Digit Coding (SDC) test. This might be attrib-
utable to the requirements of the test in CNS VS, where the 
subject presses different numbers on the keyboard based on 
the item. This involves computer familiarity and visuospatial 
scanning of the keyboard. Stroop I and III require the same 
simple motor response (pressing the space bar) to targets 
presented in the middle of the screen, which limits those fac-
tors. From our results, it does remain unclear whether pro-
cessing speed underlay the prognostic effect of both Stroop 
tests, or if executive control exhibited a unique influence. 
Adopting different tests with varying speed and executive 
components might help to explore distinct contributions.
We acknowledge other limitations in this study that could 
also be addressed in future research. Firstly, we used cog-
nitive status and KPS at one time-point instead of change 
therein. As a result, we cannot infer whether poor cognitive 
(and functional) performance reflected aggressive deteriora-
tion after surgery or a poor status that was already present. 
Future investigations might therefore include a short-term 
Fig. 2  Multivariate survival probabilities (y axis) over time (in 
months, x axis). Plots indicate impairment status on Stroop III (upper 
row) and Stroop I (lower row), under different salvage treatments. 
The dotted line (—) indicates non-impaired performance, the solid 
line (---) indicates impaired performance.
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repeated measure of KPS and a cognitive classification that 
creates subgroups of patients that go from unimpaired pre-
operative to impaired post-operative performance, indicating 
fast cognitive deterioration, and those who show impaired 
pre- and post-surgical status, indicating stable problematic 
functioning. Due to restrictions in sample size (valid T0 
NPA and/or T0 KPS were not available for all patients), we 
were unable to perform these analyses in the current sam-
ple. In addition, we did not adopt IDH1 mutation status in 
our analyses, as it was available for only 66 patients. IDH1 
mutation status is a major factor in distinguishing GBM 
subtypes [38] and predicting clinical outcome [39], but has 
also been related to cognition [40]. The high proportion of 
wild type tumors in the subsample was in line with data 
presented in the 2016 WHO Classification [37]. Still, we can 
not conclude that our results are directly applicable to the 
small proportion of IHD1 mutated glioblastoma. Conducting 
NPA three months after surgery coupled with regular care 
appointments has benefits from a logistical standpoint and 
allows for major stress from diagnosis and surgical interven-
tion to subside. We have, however, observed in our study that 
this is a subgroup of patients who are clinically able and also 
willing return at this time.
Survival outcomes of patients with brain tumors in rela-
tion to cognition have primarily been reported using the 
hazard function, summarizing a predictor’s effect in terms 
of rates of death in different groups. Models based on the 
survival curve, such as AFT [21], may be more useful if a 
predictor is thought to convey a delay in the event occur-
ring rather than an effect on the event itself occurring, 
and its derivative (Time Ratio) is arguable more clinically 
interpretable [41]. The AFT model as used here therefore 
appears to be an appropriate alternative to the commonly 
used Proportional Hazards model.
Conclusion
In conclusion, patients with GBM who displayed impair-
ment on tests of executive functioning (Stroop III) and 
processing speed (Stroop I) three months after surgical 
resection had significantly reduced survival time (26% and 
23% shorter respectively) compared to patients who did 
not show impairment. As KPS remains a principal clini-
cal prognostic factor at the three-month time-point, tar-
geted assessment of cognitive status incorporated as part 
of clinical follow-up care might allow for early refinement 
of disease monitoring. Further exploration of the prog-
nostic value of different (speeded) measures of executive 
functioning and use of AFT models are recommended.
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